{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:37:14Z","timestamp":1777451834479,"version":"3.51.4"},"reference-count":31,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2010,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatitis C antiviral therapies have significant psychiatric side effects. It is therefore believed that they might exacerbate mental illness in patients with preexisting psychiatric disorders, resulting in poor adherence and response to antiviral treatment. We aimed to assess adherence to treatment, virological outcomes and mental safety in psychiatric patients, compared with non-psychiatric patients, treated for hepatitis C.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cohort study involved unselected hepatitis C patients on scheduled therapy with pegylated interferon-\u03b12b and ribavirin, between 2002 and 2005 in France, and followed-up until 6 months after the end of treatment. Virological response was reported by the physician according to standard definitions and adverse events were monitored. Adherence to treatment was assessed by patient report.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 1,860 patients, 403 (22%) had preexisting psychiatric disorders, mostly depressive and anxiety disorders. Strict adherence was similar in psychiatric and non-psychiatric patients (35% versus 39%; P=0.20) as was the rate of sustained virological response (52% versus 51%; P=0.75). Conversely the rate of mental adverse events was higher in psychiatric patients (78% versus 57%; P&lt;0.001). Baseline characteristics independently associated with the risk of later mental adverse events were history of depression, initial pegylated interferon-\u03b12b dose and female gender.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Antiviral therapy in hepatitis C patients with associated psychiatric disease appears as effective as in other patients but results in a higher rate of mental adverse events, emphasizing the need for close monitoring of these psychiatric patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3851\/imp1566","type":"journal-article","created":{"date-parts":[[2010,6,22]],"date-time":"2010-06-22T10:36:23Z","timestamp":1277202983000},"page":"599-606","source":"Crossref","is-referenced-by-count":11,"title":["Pegylated Interferon-\u03b12b plus Ribavirin Therapy in Patients with Hepatitis C and Psychiatric Disorders: Results of a Cohort Study"],"prefix":"10.1177","volume":"15","author":[{"name":"the CheObs Study Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Philippe","family":"Lang","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Addiction, Hospital of Erstein, Erstein, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Melin","sequence":"additional","affiliation":[{"name":"Department of Polyvalent Medicine, Hospital of Saint Dizier, Saint Dizier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Ouzan","sequence":"additional","affiliation":[{"name":"Department of Hepato-Gastroenterology, Arnault Tzanck Institute, Saint Laurent du Var, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Rotily","sequence":"additional","affiliation":[{"name":"ClinSearch, Bagneux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Fontanges","sequence":"additional","affiliation":[{"name":"Department of Hepato-Gastroenterology, General Hospital of Bourgoin, Bourgoin Jallieu, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Marcellin","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Beaujon Hospital, Clichy, France"},{"name":"INSERM U773 CRB3, University of Paris 7, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Chousterman","sequence":"additional","affiliation":[{"name":"Department of Hepato-Gastroentrology, Hospital of Cr\u00e9teil (CHIC), Cr\u00e9teil, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrice","family":"Cacoub","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Paris, France"},{"name":"Laboratoire I3, Immunologie-Immunopathologie-Immunoth\u00e9rapeutique, UMR 7211 (UPMC\/CNRS), U 959 (INSERM), Pierre and Marie Curie University (Paris 6), Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2010,5,1]]},"reference":[{"key":"bibr1-IMP1566","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2005.08.016"},{"key":"bibr2-IMP1566","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.34750"},{"key":"bibr3-IMP1566","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(97)80348-0"},{"key":"bibr4-IMP1566","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.1.172"},{"key":"bibr5-IMP1566","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020047"},{"key":"bibr6-IMP1566","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"bibr7-IMP1566","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02393.x"},{"key":"bibr8-IMP1566","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2006.00740.x"},{"key":"bibr9-IMP1566","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1987.00370090055011"},{"key":"bibr10-IMP1566","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2000.7880"},{"key":"bibr11-IMP1566","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.157.6.867"},{"key":"bibr12-IMP1566","first-page":"39","volume":"25","author":"Valentine A.D.","year":"1998","journal-title":"Semin Oncol"},{"key":"bibr13-IMP1566","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0614"},{"key":"bibr14-IMP1566","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1819.2000.00754.x"},{"key":"bibr15-IMP1566","first-page":"165","volume":"7","author":"Van Thiel D.H.","year":"1995","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"bibr16-IMP1566","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)04793-X"},{"key":"bibr17-IMP1566","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2000.02090.x"},{"key":"bibr18-IMP1566","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50031"},{"key":"bibr19-IMP1566","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.01.020"},{"key":"bibr20-IMP1566","doi-asserted-by":"publisher","DOI":"10.2190\/1336-74M1-1718-73G1"},{"key":"bibr21-IMP1566","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01425.x"},{"key":"bibr22-IMP1566","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21791"},{"key":"bibr23-IMP1566","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04258-6"},{"key":"bibr24-IMP1566","unstructured":"American Psychiatric Association. [Diagnostic and statistical manual of mental disorders. 4th ed. Text revision]. Paris: Masson 2003. French."},{"key":"bibr25-IMP1566","unstructured":"Lepl\u00e8ge A., Cosse E., Pouchot J., Coste J., Perneger T. [Medical Outcome Study Short Form 36 item health survey. User manual and interpretation guide scores.] Paris: Editions Estem 2001. French."},{"key":"bibr26-IMP1566","doi-asserted-by":"publisher","DOI":"10.1016\/j.gcb.2008.10.011"},{"issue":"1","key":"bibr27-IMP1566","first-page":"2S","volume":"26","year":"1997","journal-title":"Hepatology"},{"key":"bibr28-IMP1566","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(99)80154-8"},{"key":"bibr29-IMP1566","first-page":"S3","volume":"36","author":"National Institutes of Health.","year":"2002","journal-title":"Hepatology"},{"key":"bibr30-IMP1566","first-page":"B303","volume":"26","author":"Agence Nationale d'Accr\u00e9ditation et d'Evaluation en Sant\u00e9 (ANAES).","year":"2002","journal-title":"Gastroenterol Clin Biol"},{"key":"bibr31-IMP1566","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00731.x"}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP1566","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP1566","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:49:30Z","timestamp":1777380570000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3851\/IMP1566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["10.3851\/IMP1566"],"URL":"https:\/\/doi.org\/10.3851\/imp1566","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}